Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Rhea-AI Summary
Sanuwave Health (NASDAQ: SNWV) reported preliminary Q4 2025 revenue of $13.3–$13.4 million, a 29–30% increase versus Q4 2024 and the company’s highest quarterly revenue ever. Full-year 2025 revenue rose to $44.3–$44.4 million, up 36% year-over-year and a record for the company. Management said Q4 results are within prior guidance and are based on preliminary quarter-end analysis that may be adjusted during financial close. The company noted market disruption from reduced reimbursement for skin-substitutes and allografts, and said it is adding partners and sales channels while adapting its business model. Final audited results and further detail will be released with the March earnings report.
Positive
- Q4 revenue of $13.3–$13.4M, a 29–30% YoY increase
- Full-year 2025 revenue of $44.3–$44.4M, +36% YoY (record)
- Q4 results within prior guidance, indicating execution vs plan
Negative
- Preliminary results may be adjusted during quarter-end close
- Market disruption from reduced reimbursement for skin-substitutes and allografts could pressure near-term demand
- Company undergoing business model transition, which could create execution risk
News Market Reaction – SNWV
On the day this news was published, SNWV gained 1.24%, reflecting a mild positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $282M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SNWV was up 1.12% while peers showed mixed moves: TCMD, CLPT, and NPCE were modestly positive (up to 2.29%), whereas DCTH and RXST declined as much as -2.85%, suggesting stock-specific factors rather than a broad Medical Devices move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Conference participation | Neutral | +1.4% | Announcement of participation in the J.P. Morgan Healthcare Conference. |
| Dec 08 | Commercial partnership | Positive | -8.6% | UltraMIST added to Healogics iSupply GPO for broader wound-care access. |
| Nov 07 | Quarterly earnings | Positive | +17.7% | Record Q3 2025 revenue with strong profitability and raised visibility on outlook. |
| Nov 03 | Earnings call notice | Neutral | +0.3% | Scheduling of Q3 2025 financial results conference call and webcast. |
| Nov 03 | Reimbursement update | Neutral | -5.3% | CMS final 2026 fee schedule keeping UltraMIST reimbursement largely unchanged. |
Earnings and revenue-focused updates have often coincided with positive price reactions, while partnership or reimbursement-related news has sometimes seen negative follow-through.
Over the last six months, Sanuwave has repeatedly reported record revenues, including Q1–Q3 2025 results and several preliminary quarterly updates, with growth often above 20% year over year. Earnings and preliminary revenue releases (e.g., Q2 and Q3 2025) frequently led to double‑digit percentage moves. Operational and reimbursement updates, such as CMS rate decisions and GPO additions, showed more mixed price responses. Today’s preliminary Q4 and full‑year 2025 revenue update continues the pattern of highlighting strong top‑line momentum.
Market Pulse Summary
This announcement reported preliminary Q4 2025 revenue of $13.3–$13.4M, up 29–30% year over year, and full‑year 2025 revenue of $44.3–$44.4M, up 36%, both record levels for Sanuwave. Management noted that results tracked prior guidance despite reimbursement changes in parts of the wound‑care market. Investors may focus on the March earnings release for profitability details, updated guidance, and further commentary on how evolving reimbursement and new sales channels affect future growth.
Key Terms
fda-approved regulatory
allografts medical
AI-generated analysis. Not financial advice.
Sanuwave is pleased to announce preliminary revenues of
Q4 2025 revenue increased between
Full Year 2025 revenue increased to
EDEN PRAIRIE, Minn., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the fourth quarter of 2025 are expected to be in the range of
“We’re pleased to once more be on guidance and on track for Q4 and for full year 2025,” said CEO Morgan Frank. “As we discussed when releasing Q3, the second half of 2025 was a time of intense transition in the wound care space as reductions to reimbursement rates for skin-substitutes and allografts profoundly reshaped our market. Periods of such rearrangement are always times of opportunity and Sanuwave has been busy acquiring new partners, new sales channels, and adapting its business model for, while times may change, the fact of patients in need of advanced wound care does not. This space has been a bit of a loose ball drill, and loose balls go to the one who sees them first, moves fastest, and wants them most. I am proud to say that our team excelled in all these things this quarter and it feels good to end the year with another record quarter. We look forward to sharing more about how we are positioning ourselves for the year and opportunities to come when we report earnings in March.”
The preliminary revenue results described herein are based on management’s initial analysis of the fourth quarter ended December 31, 2025, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy systems used in the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented and FDA approved/cleared energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
FAQ
What did SNWV report for Q4 2025 revenue?
How much did SNWV's full-year 2025 revenue increase?
Are the Q4 2025 SNWV results final?
Did SNWV meet its guidance for Q4 2025?
What market challenges did SNWV cite in Q4 2025?
When will SNWV release final Q4 2025 earnings?
